Abstract:
The use of phytochemical plays a major role in recent therapeutic regimens. Amongst, Capillarisin (CPS), an active chemical constituent of Artemisia capillaris was found to exert anti-inflammatory and antioxidant properties. However, the protective role of CPS has not been identified against neonatal asthma. Hence, in the present study, Wistar rats were used consisting of four groups such as control, asthma-induced, CPS-pretreated asthma animals, and CPS control. At the end of the experimental period, histology of the lungs, inflammatory cell counts in bronchoalveolar lavage fluid (BALF), inflammatory markers such as interleukin (IL) -6, IL-5, IL-4, and IL-13 were measured. Results demonstrated a significant restoration in alveolar thickening and reduced goblet cell hyperplasia with suppressed inflammatory cells. Moreover, a significant reduction in leukocyte infiltration in BALF lessened hyper responsiveness, and serum IgE levels of CPS treated group. Furthermore, the CPS administration alleviated the expression levels of IL-6, IL-17, IL-4 and IL-13 compared to the asthma-induced group. To an extent, the study elicited the extra cellular matrix protein expression in the asthma-induced animals, and the results demonstrated a profound reduction in the fibrotic markers was evidenced in CPS treated animals. Thus, the results of the present investigation propose that capillarisin can be a new medicine target for the treatment of asthma-mediated complications.
